REFERENCES
2. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 2001;201:3-11.
4. Winder M, Virós A. Mechanisms of drug resistance in melanoma. In: Mandalà M, Romano E, editors. Mechanisms of drug resistance in cancer therapy. Cham: Springer International Publishing; 2018. pp. 91-108.
5. Lim J, Cho E, Lee K, et al. Current immunotherapy approaches for malignant melanoma. BioChip J 2019;13:105-14.
8. Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 2021;18:215-29.
9. Lo JA, Kawakubo M, Juneja VR, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med 2021;13:eabd8636.
10. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 2006;6:379-89.
11. Kitano S, Tsuji T, Liu C, et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res 2013;1:235-44.
12. Friedman KM, Prieto PA, Devillier LE, et al. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 2012;35:400-8.
13. Slingluff CL, Petroni GR, Smolkin ME, et al. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund’s adjuvant for multipeptide melanoma vaccines. J Immunother 2010;33:630-8.
14. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703.
15. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). J Immunother Cancer 2021;9:e000934.
16. Melssen MM, Petroni GR, Chianese-Bullock KA, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients. J Immunother Cancer 2019;7:163.
17. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36.
18. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano 2020;14:12522-37.
19. Pacheco TJA, Silva VCMD, Souza DGD. Nano COVID-19 vaccines: the firsts RNA lipid nanoparticle vaccines being approved from history - review. RSD 2020;9:e20191211123.
20. Shaw JJP, Boyer TL, Venner E, et al. Inhibition of lysosomal function mitigates protective mitophagy and augments ceramide nanoliposome-induced cell death in head and neck squamous cell carcinoma. Mol Cancer Ther 2020;19:2621-33.
21. Zanieri F, Levi A, Montefusco D, et al. Exogenous liposomal ceramide-C6 ameliorates lipidomic profile, energy homeostasis, and anti-oxidant systems in NASH. Cells 2020;9:1237.
22. Barth BM, Wang W, Toran PT, et al. Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood Adv 2019;3:2598-603.
23. Zhang X, Kitatani K, Toyoshima M, et al. Ceramide nanoliposomes as a MLKL-dependent, necroptosis-inducing, chemotherapeutic reagent in ovarian cancer. Mol Cancer Ther 2018;17:50-9.
24. Li G, Liu D, Kimchi ET, et al. Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice. Gastroenterology 2018;154:1024-1036.e9.
25. Shin M, Snyder HW, Donvito G, et al. Liposomal delivery of diacylglycerol lipase-beta inhibitors to macrophages dramatically enhances selectivity and efficacy in vivo. Mol Pharm 2018;15:721-8.
26. Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol 2018;9:155.
27. Ponzoni M, Pastorino F, Di Paolo D, Perri P, Brignole C. Targeting macrophages as a potential therapeutic intervention: impact on inflammatory diseases and cancer. Int J Mol Sci 2018;19:1953.
28. Saremi SS, Shahryari M, Ghoorchian R, et al. The role of nanoliposome bilayer composition containing soluble leishmania antigen on maturation and activation of dendritic cells. Iran J Basic Med Sci 2018;21:536-45.
29. Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011:727241.
30. Fidler IJ. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Deliv Rev 1988;2:69-106.
31. Fan Y, Moon JJ. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccines (Basel) 2015;3:662-85.
32. Wang X, Quinn PJ, Yan A. Kdo2 -lipid A: structural diversity and impact on immunopharmacology. Biol Rev Camb Philos Soc 2015;90:408-27.
33. Sasaki H, White SH. Aggregation behavior of an ultra-pure lipopolysaccharide that stimulates TLR-4 receptors. Biophys J 2008;95:986-93.
34. Raetz CR, Garrett TA, Reynolds CM, et al. Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4. J Lipid Res 2006;47:1097-111.
35. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011;30:150-82.
36. Sims K, Haynes CA, Kelly S, et al. Kdo2-lipid A, a TLR4-specific agonist, induces de novo sphingolipid biosynthesis in RAW264.7 macrophages, which is essential for induction of autophagy. J Biol Chem 2010;285:38568-79.
37. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007;316:1628-32.
38. Livingston PO, Kaelin K, Pinsky CM, Oettgen HF, Old LJ. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 1985;56:2194-200.
39. Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 2008;26:4973-80.
40. Benati D, Galperin M, Lambotte O, et al. Public T cell receptors confer high-avidity CD4 responses to HIV controllers. J Clin Invest 2016;126:2093-108.
41. Slingluff CL Jr, Yamshchikov GV, Hogan KT, et al. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. Ann Surg Oncol 2008;15:3538-49.
42. Tiet P, Berlin JM. Exploiting homing abilities of cell carriers: targeted delivery of nanoparticles for cancer therapy. Biochem Pharmacol 2017;145:18-26.
43. Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56.
44. Tassa C, Duffner JL, Lewis TA, et al. Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles. Bioconjug Chem 2010;21:14-9.
45. Socas LB, Ambroggio EE. The influence of myristoylation, liposome surface charge and nucleic acid interaction in the partition properties of HIV-1 Gag-N-terminal peptides to membranes. Biochim Biophys Acta Biomembr 2020;1862:183421.
46. Stolk DA, de Haas A, Vree J, et al. Lipo-based vaccines as an approach to target dendritic cells for induction of T- and iNKT cell responses. Front Immunol 2020;11:990.
47. Hu Y, Kim H, Blackwell CM, Slingluff CL Jr. Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 2015;262:456-64; discussion 462.
48. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 2009;69:9012-9.
49. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375:1845-55.
